TC Biopharm Announces Corporate Restructuring, Reduction In Overhead; Co. Is Reducing Its Workforce Up To 30%, With The Majority Of The Reduction Expected To Be Completed During The First Half 2023; Expected To Result In Cost Savings In Excess Of $3M
TC Biopharm Announces Corporate Restructuring, Reduction In Overhead; Co. Is Reducing Its Workforce Up To 30%, With The Majority Of The Reduction Expected To Be Completed During The First Half 2023; Expected To Result In Cost Savings In Excess Of $3M
- Extends cash runway
- Realigned to reflect corporate strategic vision
- 擴展現金跑道
- 重新調整以反映企業戰略願景
EDINBURGH, Scotland, March 22, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced a corporate restructuring plan to reduce costs and prioritize its pending lead US clinical programs.
蘇格蘭愛丁堡，2023 年 3 月 22 日/新聞通訊/-TC 生物醫藥（控股）PLC（「TC BioCharm」或「公司」）（NASDAQ：TCBP）是一家開發平台同種異體 γ-三角洲 T 細胞治療癌症的臨床階段生物技術公司，今天宣布了一項企業重組計劃，以降低成本並優先考慮其美國領先臨床計劃。
In connection with the restructuring, the Company is reducing its workforce up to 30%, with the majority of the reduction expected to be completed during the first half 2023. The remaining team will support both current and future clinical trials and combination trials of our lead therapeutic TCB-008, as well as the allogeneic CAR modified gamma delta program. In total, these restructuring actions are expected to result in cost savings in excess of $3 million on an annual basis. This an initial step the Company is taking to reduce its cost structure and to streamline operations in line with an updated corporate strategy, reflecting a focus on combination trials with TCB-008 as well as the Company's US clinical trial strategy. TCBP will continue to implement additional cost savings programs and review non-dilutive funding options as well as strategic collaborations and partnerships.
在重組方面，公司將員工減少達 30%，預計將於 2023 年上半年完成大部分減少。其餘團隊將支持我們的鉛治療 TCB-008 的當前和未來臨床試驗以及聯合試驗，以及同種異體 CAR 改性伽馬增量計劃。總體而言，這些重組行動預計將導致每年節省超過 300 萬美元的成本。這是公司為降低成本結構並根據更新的企業策略簡化運營而採取的初步步驟，反映了與 TCB-008 的聯合試驗以及公司的美國臨床試驗策略的重點。TCBP 將繼續實施其他成本節約計劃，並審查非稀釋性資金選項以及戰略合作和合作夥伴關係。
"To address the current market realities and the macro headwinds facing biotechnology companies, we are enacting critical plans to protect TC BioPharm's long-term sustainability and ensure our growth plans are properly capitalized," said Bryan Kobel, Chief Executive Officer of TC BioPharm. "The decision to realign our resources, including human capital and cash, and restructure the organization was difficult but will help us focus on the critical programs that are expected to improve the lives of patients and establish long-term value for shareholders."
TC BioCharm 首席執行官 Bryan Kobel 表示：「為了解決當前市場現實和生物技術公司面臨的宏觀不利因素，我們正在制定關鍵計劃，以保護 TC BioCharm 的長期可持續性並確保我們的增長計劃得到適當的資本。「重新調整我們的資源（包括人力資本和現金）以及重組組織的決定很困難，但將幫助我們專注於可以改善患者生活並為股東建立長期價值的關鍵計劃。」
Kobel continued, "Our restructuring is focused on aligning the business to capitalize on a multitude of opportunities, including combination therapies driven by interest from existing collaborations and partnerships, our CAR modified program with ovarian cancer as our planned indication, as well as strategic and investor feedback. We view our lead asset, TCB-008 as an ideal candidate for numerous areas of the treatment paradigm with patients, leading to a substantial market opportunity across cancer indications and a recurring revenue model. In order for our team to capitalize fully on these potential strategic partnerships, we have taken the necessary steps to reorganize our divisions to reflect both expertise as well as capital needs. We are extremely grateful for their contributions and dedication that have enabled us to advance TCBP and helped laid the foundation for the opportunities we are now looking to capitalize on near term."
Kobel 繼續說道：「我們的重組專注於調整業務以利用眾多機會，包括由現有合作和合作夥伴關係帶動的聯合療法，我們的 CAR 修改了卵巢癌的計劃作為我們計劃的指示，以及戰略和投資者反饋。我們將我們的主要資產 TCB-008 視為患者治療範式的眾多領域的理想候選人，從而在癌症適應症和經常性收入模型方面取得了巨大的市場機會。為了使我們的團隊充分利用這些潛在的戰略合作夥伴關係，我們已採取必要的步驟來重組我們的部門，以反映專業知識和資本需求。我們非常感謝他們的貢獻和奉獻精神，這使我們能夠推進 TCBP，並為我們現在希望短期利用的機會奠定了基礎。」
譯文內容由第三人軟體翻譯。